Health Partners
A part of Jefferson Health Plans

HEALTH PARTNERS PLANS
Phone 215-991-4300 Fax 1-866-240-3712

FAX FORM AND CLINICAL DOCUMENTATION

OBESITY TREATMENT AGENTS PRIOR AUTHORIZATION FORM *(form effective 1/9/2023)*

Prior authorization guidelines for **Obesity Treatment Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

☐New request ☐Renewal request	# of pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:		
Strength & package size:	Quantity:	Refills:
Directions:		
Diagnosis *(submit documentation)*:		Dx code (*required*):
For a non-preferred Anti-Obesity Agent, does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to the preferred Anti-Obesity Agents appropriate for the beneficiary's diagnosis or indication? *Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.*		☐Yes ☐No *Submit documentation.*
For a controlled substance Obesity Treatment Agent (e.g., phentermine, Qsymia, etc.), did the prescriber or prescriber's delegate search the PDMP to review the beneficiary's controlled substance prescription history before issuing this prescription for the requested agent?		☐Yes ☐No *Submit documentation.*
Does the beneficiary have any contraindications to the requested medication?		☐Yes ☐No *Submit documentation.*
ATTESTATION from the prescriber: Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?		☐Yes ☐No

Complete all sections that apply to the beneficiary and this request.

Check all that apply and submit documentation for each item

INITIAL requests

1. The beneficiary is 18 years of age or older:

Pre-treatment weight: _____ Pre-treatment BMI: _____

☐ Has a BMI greater than or equal to 30 kg/m^2

☐ Has a BMI greater than or equal 27 kg/m^2 and less than 30 kg/m^2 and at least one of the following comorbidities:

- ☐ dyslipidemia
- ☐ hypertension
- ☐ metabolic syndrome
- ☐ other (list): _____ _____
- ☐ obstructive sleep apnea
- ☐ prediabetes
- ☐ type 2 diabetes

☐ Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. and at least one of the following comorbidities:

- ☐ dyslipidemia
- ☐ hypertension
- ☐ metabolic syndrome
- ☐ other (list): _____ _____
- ☐ obstructive sleep apnea
- ☐ prediabetes
- ☐ type 2 diabetes

2. The beneficiary is less than 18 years of age:

Pre-treatment BMI: _____ Pre-treatment BMI z-score: _____

☐ Has a BMI in the 95th percentile or greater standardized for age and sex based on current CDC charts

☐ Has a BMI in the 85th percentile or greater standardized for age and sex based on current CDC charts and at least one of the following comorbidities:

- ☐ dyslipidemia
- ☐ hypertension
- ☐ metabolic syndrome
- ☐ other (list): _____ _____
- ☐ obstructive sleep apnea
- ☐ prediabetes
- ☐ type 2 diabetes

☐ Is a candidate for treatment based on degree of adiposity, previous bariatric surgery, etc. and at least one of the following comorbidities:

- ☐ dyslipidemia
- ☐ hypertension
- ☐ metabolic syndrome
- ☐ other (list): _____ _____
- ☐ obstructive sleep apnea
- ☐ prediabetes
- ☐ type 2 diabetes

3. Request is for Evekeo (amphetamine) ODT/tablet:

☐ The beneficiary was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history

☐ Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction

☐ Has a history of trial and failure of or a contraindication or an intolerance of all other Obesity Treatment Agents (preferred and non-preferred)

☐ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering

☐ **For a beneficiary with a history of substance dependency, abuse, or diversion:**

- ☐ Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances

RENEWAL requests

1. **All requests:**
   - ☐ The dose of the requested medication is currently being titrated
   - ☐ The beneficiary is experiencing clinical benefit and/or a positive response to treatment with the requested medication
2. **The beneficiary is 18 years of age or older:**

   Pre-treatment weight: _____ Current weight: _____
3. **The beneficiary is less than 18 years of age:**

   Pre-treatment BMI: _____ Current BMI: _____

   Pre-treatment BMI z-score: _____ Current BMI z-score: _____
4. **Request is for Evekeo (amphetamine) ODT/tablet:**
   - ☐ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering (*submit documentation)*
   - ☐ **For a beneficiary with a history of substance dependency, abuse, or diversion:**
     - ☐ Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 866-240-3712

Prescriber Signature:	**Date**: